CLAIMS

1. A composition comprising an effective amount of glyceryl linoleate, glyceryl linolenate, xymenynic acid, and *Pterocarpus Marsupium* bark extract.

2. The composition of claim 1, wherein the effective amount of glyceryl linoleate is 75% to 94% by weight of the composition.

3. The composition of claim 1, wherein the effective amount of glyceryl linolenate is 5% to 10% by weight of the composition.

4. The composition of claim 1, wherein the effective amount of xymenynic acid is 5% to 10% by weight of the composition.

5. The composition of claim 1, wherein the effective amount of *Pterocarpus Marsupium* bark extract is 1% to 5% by weight of the composition.

6. The composition of claim 1, wherein the effective amount of glyceryl linoleate is 75% to 94% by weight of the composition, glyceryl linolenate is 5% to 10% by weight of the composition, xymenynic acid is 5% to 10% by weight of the composition, and *Pterocarpus Marsupium* bark extract is 1% to 5% by weight of the composition.

7. A topical formulation comprising a composition of an effective amount of the following PPAR agonists: glyceryl linoleate, glyceryl linolenate, xymenynic acid, and Pterocarpus Marsupium bark extract, and pharmaceutically or cosmetically acceptable excipients, wherein the formulation is suitable for topical administration.

8. The topical formulation of claim 7, wherein glyceryl linoleate is in an amount of 0.375% to 4.7% by weight of the topical formulation.

9. The topical formulation of claim 7, wherein glyceryl linolenate is in an amount of 0.025% to 0.5% by weight of the topical formulation.

10. The topical formulation of claim 7, wherein xymenynic acid is in an amount of 0.025% to 0.5% by weight of the topical formulation.

11. The topical formulation of claim 7, wherein *Pterocarpus Marsupium* bark extract is in an amount of 0.005% to 0.25% by weight of the topical formulation.

12. Use of the topical formulation of claim 7 in the manufacture of a medicament for inducing skin barrier repair comprising topically administering a topical formulation of claim 7.

13. The use of claim 12, wherein inducing skin barrier repair results in the biosynthesis of barrier lipids and proteins in the skin selected from the group consisting of ceramides, filaggrin, trans-glutaminase 1, TGFB1, keratins, LCE1D, CERS3, CDH1, FOXO1, HSP27, involucrin, loricrin, beta-glucocerebrosidase, aquaporin 3, ABCA12, ADRP, FIAF, and combinations thereof.

14. The use of claim 12, wherein inducing skin barrier repair results in the modulation of the expression of barrier genes in the skin selected from the group consisting of ceramides, filaggrin, trans-glutaminase 1, TGFB1, keratins, LCE1D, CERS3, CDH1, FOXO1, HSP27, involucrin, loricrin, beta-glucocerebrosidase, aquaporin 3, ABCA12, ADRP, FIAF and combinations thereof.

15. Use of the topical formulation of claim 7 in the manufacture of a medicament for improving aging skin.

16. The use of claim 15, wherein the improvement of aging skin is selected from the group consisting of smoothness, hydration and texture.

17. Use of the topical formulation of claim 7 in the manufacture of a medicament for preventing skin damage.

18. Use of the topical formulation of claim 7 in the manufacture of a medicament for improving the look of skin.

19. Use of the topical formulation of claim 7 in the manufacture of a medicament for calming and soothing irritated skin.

20. Use of the topical formulation of claim 7 in the manufacture of a medicament for treating atopic dermatitis (eczema).

21. Use of the topical formulation of claim 7 in the manufacture of a medicament for treating photo-damage and hyperpigmentation.

22. Use of the topical formulation of claim 7 in the manufacture of a

medicament for improving skin barrier function.

23. Use of the topical formulation of claim 7 in the manufacture of a medicament for improving skin surface texture.

24. Use of the topical formulation of claim 7 in the manufacture of a medicament for providing desquamation.

25. Use of the topical formulation of claim 7 in the manufacture of a medicament for improving skin brightening.

26. Use of the topical formulation of claim 7 in the manufacture of a medicament for mitigating irritation.

27. Use of the topical formulation of claim 7 in the manufacture of a medicament for supporting the skin's natural ability to defend itself against environmental stressors.

28. Use of the topical formulation of claim 7 in the manufacture of a medicament for stimulating hair growth.

29. Use of the topical formulation of claim 7 in the manufacture of a medicament for maintaining healthy hair.

30. Use of the topical formulation of claim 7 in the manufacture of a medicament or a cosmetic product for increasing hair density and volume.

31. Use of the topical formulation of claim 7 in the manufacture of a medicament for improving the look and feel of hair.

32. Use of the topical formulation of claim 7 in the manufacture of a medicament for treating acne.

33. Use of the topical formulation of claim 7 in the manufacture of a medicament for decreasing inflammation and irritation caused by acne lesions.

34. Use of the topical formulation of claim 7 in the manufacture of a medicament for inhibiting P. acnes.

35. Use of the topical formulation of claim 7 in the manufacture of a medicament for preventing follicle clogging.

36. Use of the topical formulation of claim 7 in the manufacture of a medicament for reducing the number of acne lesions .